Dermapharm floats to finance growth
This article was originally published in OTC Bulletin & The Rose Sheet
German OTC and generics specialist Dermapharm is looking to raise around €100 million through an initial public offering (IPO) on the Frankfurt Stock Exchange during the first half of this year.
You may also be interested in...
Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
The new EU regulation on increasing powers of the European Medicines Agency in future health crises applies as of 1 March; it controversially sees the agency become more involved in device oversight.